Alessandro Gronchi, Chair of the Department of Surgical Oncology at the National Cancer Institute of Milan, shared a post on LinkedIn:
“At ESMO – European Society for Medical Oncology Sarcoma and Rare Cancers Meeting in Lugano a full house attended the engaging session about neoadjuvant therapies in high-risk soft tissue sarcoma.
A new study is on the horizon which will test the combination of immune checkpoint inhibitors and anthracycline-based chemotherapy +/- radiotherapy.
All attendees agreed that this is the study to do in sarcomas. And a parallel observational study will also be done to include all patients treated off randomized trial at the participating institutions, taking the example of STREXIT and STREXIT2 in retroperitoneal sarcoma.
This incredible sarcoma community can make it!”
Alessandro Gronchi
More posts featuring Alessandro Gronchi.
